LAS VEGAS, Jan. 4, 2022 /PRNewswire/ — JanOne Inc. (Nasdaq: JAN), an organization that focuses on the event of medication with non-addictive, pain-relieving properties – in an effort to additional scale back the drug habit epidemic – beforehand introduced an choice settlement for the rights to a novel technique to scale back methamphetamine (meth) use by activating the Translocator Protein 18 kDa (TSPO). Though meth use has been reducing in youthful people, in individuals over 26 years outdated, it has been rising at a CAGR of 13% p.a., with simply over 150,000 new customers of the drug yearly. The demise fee of drug overdoses have elevated by over 300% within the final 10 years. Though the projected marketplace for therapies of methamphetamine abuse is near $500M, there are not any FDA-approved drugs for the therapy of methamphetamine use dysfunction.
“We’re very excited to kick-off our analysis into new therapies for methamphetamine use dysfunction,” commented Tony Isaac, JanOne Inc.’s Chief Government Officer. “JanOne’s mission is to affect the opioid disaster in America. With over 40% of meth customers concurrently utilizing opioids, we’re hopeful that this program is not going to solely affect the meth downside, but additionally play a job in decreasing opioid abuse and deaths.”
JanOne Inc. has recognized world-class collaborators and anticipates initiating a drug discovery program in 2022, with the objective of figuring out a preclinical IND-candidate in 2023. This represents an extra therapeutic effort in JanOne Inc.’s pipeline, with the corporate anticipating starting a important Section 2b trial with JAN101 in late 2022.
Ahead Wanting Statements
This press launch accommodates statements which might be forward-looking statements as outlined throughout the Personal Securities Litigation Reform Act of 1995, together with, however not restricted to, statements referring to the truth that JAN101 will deal with PAD, the timing of the graduation of medical trials, that the FDA will allow approval via a 505(b)(2) pathway, that upon approval JAN101 will instantly disrupt the PAD market, and different statements together with phrases equivalent to “proceed”, “count on”, “intend”, “will”, “hope” “ought to”, “would”, “could”, “potential” and different comparable expressions. Such statements mirror JanOne Inc.’s present view with respect to future occasions, are topic to dangers and uncertainties, and are essentially primarily based upon various estimates and assumptions that, whereas thought of affordable by JanOne Inc., are inherently topic to vital enterprise, financial, aggressive, political and social uncertainties and contingencies. Many elements might trigger JanOne Inc.’s precise outcomes, efficiency or achievements to be materially totally different from any future outcomes, efficiency or achievements described on this press launch. Such elements might embrace, amongst others, these detailed within the Firm’s periodic stories filed with the Securities and Change Fee (the “SEC”).
Ought to a number of of those dangers or uncertainties materialize, or ought to the assumptions set out within the part entitled “Danger Components” in JanOne Inc.’s filings with the USA Securities and Change Fee underlying these forward-looking statements show incorrect, precise outcomes could differ materially from these described herein. These forward-looking statements are made as of the date of this press launch and JanOne Inc. does not intend, and doesn’t assume any obligation, to replace these forward-looking statements, besides as required by legislation. JanOne Inc. can’t guarantee that such statements will show to be correct as precise outcomes and future occasions might differ materially from these anticipated in such statements. People are cautioned that forward-looking statements aren’t ensures of future efficiency and accordingly buyers are cautioned to not put undue reliance on forward-looking statements as a result of inherent uncertainty therein.
About JanOne Inc.
JanOne Inc. is a singular Nasdaq-listed firm providing revolutionary, actionable options that it believes will help create an finish to the opioid disaster. JanOne Inc. is devoted to funding assets towards innovation, know-how and training to discover a key decision the nationwide opioid epidemic, which is without doubt one of the deadliest and widespread within the nation’s historical past. The corporate continues to function its legacy companies – ARCA Recycling and GeoTraq – beneath their present model names. JanOne Inc’s subsidiary, ARCA Recycling, recycles family home equipment by offering turnkey recycling and substitute companies for utilities and different sponsors of power effectivity applications. JanOne Inc.’s subsidiary GeoTraq engages within the growth, design and, in the end, anticipated sale of Cellular IoT modules. Please go to www.janone.com for extra data.
Investor Relations & Media Contact
1 (800) 400-2247
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/janone-inc-develops-plan-for-treating-methamphetamine-use-disorder-301453426.html
SOURCE JanOne Inc.